Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11-hydroxyamentadione is a natural meroditerpenoid isolated from the brown macroalga *Cystoseira usneoides*. It exhibits significant antioxidant, anti-inflammatory, and antiplatelet properties. In preclinical and ex vivo studies, 11-hydroxyamentadione has been shown to inhibit arachidonic acid-induced platelet aggregation at low micromolar concentrations, prevent thromboxane B2 (TXB2) formation, and mildly inhibit intracellular calcium transport. Additionally, it suppresses the production of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) in lipopolysaccharide (LPS)-stimulated human macrophages, indicating potential therapeutic utility in cardiovascular and inflammatory disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11-hydroxyamentadione.